Applications including "United States Pharmacopeia"
-
LB876 - Analysis of Cefoxitin -
LC InertSearch InertSustain C18 -
LB875 - Analysis of Levofloxacin -
LC InertSearch Inertsil ODS-3 -
LB874 - Analysis of Captopril and Captopril Disulfide -
LC InertSearch InertSustain AQ-C18 -
LB873 - Tacrolimus Extended-Release Capsules -
LC InertSearch InertSustain AQ-C18 -
LB872 - Analysis of Febuxostat -
LC InertSearch InertSustain Phenyl -
LB871 - Analysis of Febuxostat -
LC InertSearch InertSustain Phenyl -
LB870 - Analysis of Febuxostat -
LC InertSearch InertSustain Phenyl -
LB867 - Analysis of Febuxostat -
LC InertSearch InertSustain C18 -
LT159 - Assay Test for Esomeprazole Magnesium Delayed -Release Capsules under USP Method -
LC Technical Note InertSustain C18 -
LT099 - Analysis of Valsartan -
LC Technical Note InertSustain C18 -
LT098 - Analysis of Amlodipine -
LC Technical Note Inertsil ODS-4 HP -
LT097 - Analysis of Pioglitazone Hydrocloride -
LC Technical Note Inertsil ODS-4 HP -
LB084 - Analysis of Olmesartan medoxomil (Under the Condition of United States Pharmacopeia 35-NF30) -
LC InertSearch InertSustain C18 -
GT101 - Analysis of memantine hydrochloride in accordance with the USP -
GC Technical Note -
GA291 - Memantine Hydrochloride(Under the Condition of United States Pharmacopeia 39, Organic Impurities) -
GC InertSearch InertCap 5 -
GA290 - Memantine Hydrochloride(Under the Condition of United States Pharmacopeia 39, Assay) -
GC InertSearch InertCap 5